Your browser is no longer supported. Please, upgrade your browser.
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E- EPS (ttm)-0.11 Insider Own0.10% Shs Outstand2.26B Perf Week-2.21%
Market Cap144.75B Forward P/E8.66 EPS next Y7.45 Insider Trans-11.05% Shs Float2.23B Perf Month4.11%
Income-44.00M PEG- EPS next Q1.41 Inst Own75.90% Short Float0.67% Perf Quarter7.55%
Sales39.40B P/S3.67 EPS this Y-33.90% Inst Trans0.22% Short Ratio1.40 Perf Half Y7.83%
Book/sh22.22 P/B2.91 EPS next Y16.71% ROA0.00% Target Price74.76 Perf Year-3.45%
Cash/sh9.44 P/C6.84 EPS next 5Y21.35% ROE-0.10% 52W Range45.76 - 68.34 Perf YTD4.08%
Dividend1.96 P/FCF18.15 EPS past 5Y10.90% ROI5.50% 52W High-5.53% Beta0.62
Dividend %3.04% Quick Ratio1.60 Sales past 5Y10.50% Gross Margin71.50% 52W Low41.08% ATR1.33
Employees30000 Current Ratio1.70 Sales Q/Q75.50% Oper. Margin8.70% RSI (14)55.42 Volatility1.99% 1.91%
OptionableYes Debt/Eq0.90 EPS Q/Q-1.30% Profit Margin-0.10% Rel Volume0.85 Prev Close64.18
ShortableYes LT Debt/Eq0.82 EarningsFeb 04 BMO Payout- Avg Volume10.70M Price64.56
Recom1.90 SMA202.12% SMA502.93% SMA2006.13% Volume9,066,175 Change0.59%
Nov-16-20Upgrade Societe Generale Hold → Buy $76
Nov-10-20Resumed Bernstein Mkt Perform
Nov-06-20Downgrade Gabelli & Co Buy → Hold
Oct-19-20Upgrade Guggenheim Neutral → Buy $70
Sep-29-20Initiated Berenberg Buy $73
Jul-28-20Initiated Raymond James Outperform $75
Apr-02-20Upgrade Morgan Stanley Equal-Weight → Overweight $64
Mar-23-20Downgrade Societe Generale Buy → Hold $50
Feb-27-20Initiated Barclays Equal Weight $69
Jan-06-20Resumed Citigroup Buy $73
Dec-13-19Upgrade Argus Hold → Buy $80
Nov-22-19Resumed Morgan Stanley Equal-Weight $60
Oct-17-19Resumed BofA/Merrill Buy $60
Aug-14-19Upgrade Atlantic Equities Neutral → Overweight $63
May-28-19Initiated Goldman Buy
May-20-19Downgrade Argus Buy → Hold
May-03-19Upgrade Barclays Equal Weight → Overweight $53 → $55
May-03-19Resumed JP Morgan Overweight $62
Jan-15-19Upgrade Societe Generale Sell → Buy
Oct-22-18Downgrade Citigroup Buy → Neutral
Jan-22-21 01:18PM  
12:10PM  
12:00PM  
07:50AM  
Jan-21-21 02:43PM  
06:59AM  
Jan-20-21 06:59AM  
06:59AM  
Jan-18-21 04:10PM  
Jan-15-21 05:45PM  
12:19PM  
07:15AM  
Jan-14-21 04:35PM  
02:52PM  
Jan-12-21 05:45PM  
04:56PM  
04:31PM  
09:29AM  
Jan-11-21 04:51PM  
04:29PM  
03:42PM  
08:30AM  
08:11AM  
07:30AM  
07:04AM  
06:59AM  
Jan-10-21 09:02AM  
Jan-09-21 12:37PM  
Jan-07-21 10:02AM  
06:25AM  
Jan-06-21 05:45PM  
06:25AM  
Jan-04-21 05:23PM  
06:59AM  
06:59AM  
06:59AM  
Jan-01-21 11:16AM  
08:34AM  
06:59AM  
Dec-31-20 08:58AM  
Dec-29-20 10:25AM  
Dec-28-20 06:59AM  
Dec-26-20 01:34AM  
Dec-24-20 09:14AM  
07:34AM  
Dec-23-20 05:45PM  
10:32AM  
08:53AM  
07:52AM  
06:59AM  
Dec-21-20 06:59AM  
Dec-19-20 06:16AM  
Dec-18-20 10:15AM  
Dec-16-20 01:46PM  
06:59AM  
Dec-15-20 05:00PM  
09:53AM  
09:43AM  
08:41AM  
Dec-14-20 02:38PM  
12:59PM  
05:26AM  
Dec-11-20 05:45PM  
07:15AM  
06:59AM  
Dec-10-20 04:16PM  
Dec-09-20 08:33AM  
Dec-08-20 07:00AM  
06:59AM  
Dec-07-20 04:30PM  
12:40PM  
10:00AM  
Dec-06-20 06:12AM  
Dec-05-20 12:30PM  
11:32AM  
Dec-04-20 10:05AM  
05:51AM  
Dec-03-20 11:18AM  
Dec-01-20 02:23PM  
Nov-25-20 01:14PM  
Nov-24-20 02:54PM  
06:59AM  
06:15AM  
Nov-23-20 11:33AM  
10:33AM  
07:01AM  
06:30AM  
Nov-19-20 04:36PM  
Nov-18-20 12:24PM  
06:08AM  
01:29AM  
Nov-17-20 03:39PM  
12:43PM  
11:12AM  
09:45AM  
08:30AM  
06:59AM  
01:42AM  
Nov-16-20 07:56PM  
06:54PM  
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. The company's products include Opdivo for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia for adult patients with active RA and prostate-specific antigen, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, it offers Reyataz, a protease inhibitor to treat human immunodeficiency virus (HIV); Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. The company has collaboration agreements with Pfizer, Otsuka, Ono, Nektar, GRYT Health, Ubiquigent Limited, Checkmate Pharmaceuticals, and Sensyne Health plc; clinical collaboration with NeoImmuneTech, Inc.; partnership with Astrazeneca Plc; a discovery collaboration with Insitro, Inc.; and collaboration with Schrodinger, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Elkins David VEVP, Chief Financial OfficerDec 31Option Exercise0.0020,624079,111Jan 05 08:13 PM
VESSEY RUPERTEVP, Research & Early Dev.Dec 31Option Exercise0.0025,866068,074Jan 05 08:14 PM
AHMED NADIMEVP and President, HematologyDec 31Option Exercise0.0014,946046,549Jan 05 08:13 PM
Elkins David VEVP, Chief Financial OfficerDec 02Option Exercise0.008,792063,574Dec 03 08:24 PM
AHMED NADIMEVP and President, HematologyDec 02Option Exercise0.006,594034,983Dec 03 08:24 PM
VESSEY RUPERTEVP, Research & Early Dev.Dec 02Option Exercise0.008,792046,714Dec 03 08:24 PM
BOERNER CHRISTOPHER S.EVP, Chief Commercial OfficerDec 02Option Exercise0.002,637023,670Dec 03 08:23 PM
Eid JosephSVP,Head Glob. Medical AffairsDec 01Option Exercise0.002,82505,359Dec 03 05:15 PM
von Autenried PaulEVP, Chief Information OfficerNov 25Sale63.503191126,698Nov 30 05:52 PM
von Autenried PaulEVP, Chief Information OfficerNov 24Sale62.7520,0001,255,000126,701Nov 25 04:31 PM
Dubow AdamSVP,ChiefCompliance&EthicsOff.Nov 24Sale63.3990057,05115,186Nov 25 04:32 PM
VESSEY RUPERTEVP, Research & Early Dev.Nov 23Sale61.3413,421823,24437,922Nov 25 04:32 PM
VESSEY RUPERTEVP, Research & Early Dev.Nov 19Option Exercise49.2852,2132,572,88798,355Nov 23 05:40 PM
VESSEY RUPERTEVP, Research & Early Dev.Nov 19Sale61.3057,5913,530,26946,142Nov 23 05:40 PM
AHMED NADIMEVP and President, HematologyOct 30Option Exercise0.004,650030,680Nov 03 04:28 PM
VESSEY RUPERTEVP, Research & Early Dev.Oct 30Option Exercise0.005,804059,580Nov 03 04:27 PM
Santiago Karen MurphySVP & ControllerSep 01Option Exercise0.0064208,390Sep 02 04:33 PM
Caforio GiovanniChairman and CEOAug 31Sale62.7039,8402,497,968445,584Sep 02 04:34 PM
Eid JosephSVP,Head Glob. Medical AffairsAug 17Sale64.005,327340,9282,534Aug 19 06:15 PM
LEUNG SANDRAEVP, General CounselAug 13Sale63.24141,4208,943,401432,744Aug 17 04:55 PM
Elkins David VEVP, Chief Financial OfficerAug 01Option Exercise0.0046,402080,698Aug 04 04:43 PM
Hirawat SamitEVP,Chief Med.Offr.,Drug Dev.Jul 01Option Exercise0.009,35609,356Jul 02 04:56 PM
Santiago Karen MurphySVP & ControllerJul 01Option Exercise0.001,06908,115Jul 02 04:54 PM
Paliwal Dinesh CDirectorJun 15Buy54.509,174499,98322,109Jun 16 05:15 PM
Haller Julia ADirectorJun 14Option Exercise0.0055806,819Jun 16 05:15 PM
BONNEY MICHAEL WDirectorJun 14Option Exercise0.0055808,650Jun 16 05:16 PM
Haller Julia ADirectorJun 13Option Exercise0.0090306,261Jun 16 05:15 PM
BONNEY MICHAEL WDirectorJun 13Option Exercise0.0090308,092Jun 16 05:16 PM
Eid JosephSVP,Head Glob. Medical AffairsJun 03Option Exercise0.002,15408,599Jun 09 07:15 PM
Haller Julia ADirectorJun 03Option Exercise0.002,94905,358Jun 05 04:39 PM
BONNEY MICHAEL WDirectorJun 03Option Exercise0.002,94907,189Jun 05 04:40 PM
Dubow AdamSVP,ChiefCompliance&EthicsOff.May 22Sale61.013,200195,23216,086May 26 05:17 PM
Schmukler Louis SEVP,Pres.,Glob.Prod. & SupplyMay 19Sale62.6825,0001,567,00026,777May 21 05:22 PM
VESSEY RUPERTEVP, Research & Early Dev.May 01Option Exercise0.0010,707059,050May 05 04:49 PM
AHMED NADIMEVP and President, HematologyMay 01Option Exercise0.002,908027,463May 05 04:49 PM
Schmukler Louis SEVP,Pres.,Glob.Prod. & SupplyMar 10Option Exercise0.0030,519058,379Mar 12 06:18 PM
von Autenried PaulEVP, Chief Information OfficerMar 10Option Exercise0.0020,8060152,400Mar 12 06:19 PM
Powell AnnEVP, Chief Human ResourcesMar 10Option Exercise0.0031,169058,421Mar 12 06:17 PM
Santiago Karen MurphyControllerMar 10Option Exercise0.005,06307,778Mar 12 06:17 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0051,5980588,175Mar 12 06:15 PM
Eid JosephSVP,Head Glob. Medical AffairsMar 10Option Exercise0.001,57106,652Mar 12 06:13 PM
Elicker John EEVP, Investor RelationsMar 10Option Exercise0.0018,407075,102Mar 12 06:14 PM
Caforio GiovanniChairman and CEOMar 10Option Exercise0.00211,7960544,032Mar 12 06:11 PM
Dubow AdamSVP,ChiefCompliance&EthicsOff.Mar 10Option Exercise0.005,007020,091Mar 12 06:12 PM
Bancroft Charles AEVP, Head of IntegrationMar 10Option Exercise0.0071,8680153,637Mar 12 06:11 PM
BOERNER CHRISTOPHER S.EVP, Chief Commercial OfficerMar 10Option Exercise0.0021,426026,091Mar 12 06:11 PM
Elicker John EEVP, Investor RelationsMar 04Sale61.0115,805964,26358,666Mar 06 05:20 PM
VESSEY RUPERTPres., Research & Early Dev.Mar 02Option Exercise51.6993,4684,831,452132,651Mar 04 06:19 PM
VESSEY RUPERTPres., Research & Early Dev.Mar 02Sale60.5984,3085,108,22248,343Mar 04 06:19 PM
AHMED NADIMPresident, HematologyMar 01Option Exercise0.0017,204033,028Mar 03 08:04 PM
Elkins David VEVP, Chief Financial OfficerMar 01Option Exercise0.0024,579044,766Mar 03 08:04 PM
VESSEY RUPERTPres., Research & Early Dev.Mar 01Option Exercise0.0023,349048,106Mar 03 08:05 PM
AHMED NADIMPresident, HematologyFeb 04Option Exercise0.002,076016,895Feb 06 08:48 PM
VESSEY RUPERTPres., Research & Early Dev.Feb 04Option Exercise0.003,592025,920Feb 06 08:49 PM